Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) <i>BRCA</i> mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.Jacob Korach, Éric Pujade-Lauraine, Simon Turner et al.|Journal of Clinical Oncology|2018Cited by 17
Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancerS.N. Westin, Robert L. Coleman, Amir A. Jazaeri et al.|Annals of Oncology|2017Cited by 16
2752 Early-onset anaemia does not affect clinical activity of olaparib in advanced ovarian cancer patients: Pooled analysis of nine studiesAntoine Thiery-Vuillemin, Jane Robertson, P.A. Galer-Frost et al.|European Journal of Cancer|2015Cited by 0